3 New Strong Buy Ratings from Top-Rated Analysts: 09/26/2025
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Why Worthington Steel (WS) is gaining momentum from acquisition potential
- Neurocrine Biosciences (NBIX): A rare biopharma with strong financials
- With a fantastic earnings guidance upgrade, Tutor Perini (TPC) appears poised for great things
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
How to Become Your Own Bank (And Earn 30-400% Annually) A former Wall Street insider with a CFA Charter is showing crypto investors how to "become their own bank". This select group is using the same liquidity strategy BlackRock uses to dominate traditional markets... except in crypto where returns are exponentially higher. This allows them to generate income regardless of market direction. Regular investors are already earning up to triple-digit annual returns. Click here for the free training to learn how you can earn an extra 30-400% on your digital assets.1. Worthington Steel (NYSE: WS)
Worthington Steel is a newly independent steel processor with deep roots in the industry, spun off from Worthington Industries in 2023 to sharpen its focus on flat-rolled steel solutions. With an emphasis on advanced high-strength and coated steels and a push into lighter and more sustainable materials, WS is poised to benefit from industry trends.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $33.74 — get current quote >
Max 1-year forecast: $36.00
Why we’re watching:
- Worthington Steel is quite low-profile — the stock has 1 Strong Buy rating. See the ratings
- That Strong Buy rating was recently reiterated by KeyBanc’s Matthew Gillmor (a top 9% rated analyst), who also raised his price target from $34 to $36.
- Factors favoring Worthington Steel's momentum over the next 6 to 12 months, according to Gillmor, include FY 2026 to 2027 estimate revisions, improved auto customer sentiment, and the potential for the company to make larger accretive acquisitions.
- WS is currently the 2nd highest-rated stock in the Steel industry, which has an Industry Rating of B.
- Worthington Steel shares rank in the 91st percentile of the equities that we track, giving them a Zen Rating of B.
- Our Artificial Intelligence Component Grade rating uses a neural network trained on two decades of market data to identify likely outperformers. In this category, WS ranks in the 84th percentile of stocks.
- Worthington Steel also ranks in the 84th percentile of equities with regard to Sentiment.
- Another vote in the stock’s favor is its valuation. WS is currently trading at a price-to-earnings (P/E) ratio of 15.02x, and a price-to-earnings growth (PEG) ratio of 0.99x, so it ranks in the top 12% in terms of Value.
- Lastly, we have Safety — the Component Grade rating that assesses stock price stability, revenue inflow consistency, and earnings predictability. Here, Worthington Steel ranks in the top 10%. (See all 7 Zen Component Grades here >)
2. Neurocrine Biosciences (NASDAQ: NBIX)
Neurocrine Biosciences is a neuroscience-focused biopharma business that maintains a growing drug pipeline targeting movement disorders, epilepsy, depression, and rare pediatric diseases. The company recently delivered a double beat, and Wall Street’s expectations are rather high — however, NBIX is still trading at a very attractive valuation.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $145.23 — get current quote >
Max 1-year forecast: $185.00
Why we’re watching:
- NBIX is tracked by 15 Wall Street equity researchers — their coverage is split between 8 Strong Buy ratings, 5 Buy ratings, and 2 Hold ratings. See the ratings
- In addition, the average 12-month price forecast for Neurocrine Biosciences shares is currently pegged at $160.53, and implies a healthy 10.54% upside.
- Morgan Stanley’s Jeffrey Hung (a top 11% rated analyst) recently maintained a Strong Buy rating on the stock, and increased his price target from $158 to $163.
- NBIX is the 9th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
- Neurocrine Biosciences ranks in the top 4% of the stocks that we track, giving it a Zen Rating of A.
- Value is one of NBIX’s strong suits — the stock ranks in the top 8% of equities in this category.
- In terms of its Artificial Intelligence Component Grade rating, Neurocrine Biosciences shares rank in the top 7%.
- Thanks to the company’s robust balance sheet, NBIX currently ranks in the 96th percentile when it comes to Financials. (See all 7 Zen Component Grades here >)
A note from our sponsors...
Here's the Best Day to Buy Stocks Did you know the S&P 500 has a 100% history of soaring, beginning on one particular day every fall? We call this the "Green Day phenomenon." It works on 5,000 stocks. For example, Nvidia has a 100% history of soaring beginning on one particular day every single year. Click here to see the green days for 7 major stocks today.3. Tutor Perini (NYSE: TPC)
TPC found a place in our exclusive Zen Investor portfolio earlier this month. It’s the highest-rated stock in its industry — it’s also one of the highest-rated stocks overall. A recent earnings beat has put the stock in the limelight — and once you see how earnings estimates have changed, you’ll likely want to scoop up some shares while they’re still relatively cheap.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $64.78 — get current quote >
Max 1-year forecast: $75.00
Why we’re watching:
- TPC is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained what makes Tutor Perini such an attractive pick in a Monday article. We’ll summarize some of the key points below.
- At present, Tutor Perini has a Zen Rating of A, and is rated 3rd overall out of the roughly 4,600 stocks that we track.
- TPC is also the highest-rated stock in the Engineering & Construction industry, which has an Industry Rating of A.
- The stock blew everyone’s mind this earnings season. While the company did provide a modest 12% earnings beat, guidance was the star of the show — earnings estimates for this year nearly doubled from $1.81 to $3.34, which has also led to an increase in earnings prospects for 2026, 2027, and beyond.
- TPC ranks in the top 26% of stocks when it comes to Value, and the top 17% in terms of Artificial Intelligence.
- However, Momentum and Growth are Tutor Perini’s strongest suits — in these categories, the stock ranks in the 96th and 99th percentile, respectively. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.